Rezolute, Inc. Stock News

REDWOOD CITY, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential t

REDWOOD CITY, Calif., May 01, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential t

Results Presented Today at the Pediatric Endocrine Society’s 2022 Annual Meeting Results Presented Today at the Pediatric Endocrine Society’s 2022 Annual Meeting

Rezolute joins group aimed at helping advance timely access to life-saving therapies for those impacted by rare diseases Rezolute joins group aimed at helping advance timely access to life-saving ther

Rezolute (RZLT) releases favorable data from the phase IIb RIZE study on its lead candidate RZ358, currently being investigated for congenital hyperinsulinism.

Rezolute (RZLT) releases favorable data from the phase IIb RIZE study on its lead candidate RZ358, currently being investigated for congenital hyperinsulinism.

The RIZE study demonstrated highly significant improvements in hypoglycemia and good safety and tolerability

Rezolute Inc (NASDAQ: RZLT ) announced topline data from its Phase 1b multiple-ascending dose (MAD) study of RZ402, a plasma kallikrein inhibitor (PKI) for diabetic macular edema (DME). Results of the MAD study further validate and support the potential for once-daily oral Full story available on Benzinga.com

Phase 2 proof-of-concept study anticipated in 2H 2022 Phase 2 proof-of-concept study anticipated in 2H 2022

Rezolute press release (RZLT): Q2 GAAP EPS of -$0.80.Cash and cash equivalents of $77.4M.“We have maintained excellent momentum and are on track to report topline data before the end…

Topline results from RZ358 Phase 2b and RZ402 Phase 1b studies expected before the end of Q1 2022 Topline results from RZ358 Phase 2b and RZ402 Phase 1b studies expected before the end of Q1 2022

Shares of Rezolute, Inc. (NASDAQ:RZLT) have been assigned an average rating of Buy from the six research firms that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average twelve-month price objective among brokerages that []

Rezolute (NASDAQ:RZLT) had its price objective lowered by Canaccord Genuity from $30.00 to $17.00 in a research report released on Monday morning, The Fly reports. Canaccord Genuity currently has a buy rating on the stock. A number of other equities analysts have also issued reports on RZLT. JMP Securities decreased their target price on shares []

Shares of Rezolute, Inc. (NASDAQ:RZLT) have earned an average recommendation of Buy from the six research firms that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average twelve-month price target among analysts that have []

Rezolute, Inc. (NASDAQ:RZLT) Equities researchers at Oppenheimer lifted their Q2 2022 EPS estimates for Rezolute in a report released on Monday, November 15th. Oppenheimer analyst K. Degeeter now anticipates that the company will post earnings of ($0.66) per share for the quarter, up from their prior estimate of ($0.91). Oppenheimer also issued estimates for []